- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
| home:starting [09.17.2017] – [Starting the Marshall Protocol] sallieq | home:starting [07.04.2022] (current) – external edit 127.0.0.1 | ||
|---|---|---|---|
| Line 23: | Line 23: | ||
| * [[home: | * [[home: | ||
| - | Important: | + | Important: |
| The MP Knowledge Base is partly based on that ongoing longitudinal study supported by the ARF and described below. | The MP Knowledge Base is partly based on that ongoing longitudinal study supported by the ARF and described below. | ||
| Line 29: | Line 29: | ||
| Anyone with one or more Auto-immune diagnoses, also anyone with long term medical problems which resist diagnosis, is invited to register. | Anyone with one or more Auto-immune diagnoses, also anyone with long term medical problems which resist diagnosis, is invited to register. | ||
| - | It is most helpful to the progress of the research, for you then to post if applicable, your decision to postpone, suspend or discontinue use of Olmesartan medoxomil with your reason(s) | + | It is most helpful to the progress of the research, for you then to post if applicable, your decision to postpone, suspend or discontinue use of Olmesartan medoxomil with your reason(s) for this decision. |
| - | + | ||
| - | where this applies, we also request a brief summary annually to follow up your welfare, in order to make it possible | + | |
| + | where this applies, we also would appreciate a brief summary annually or less frequently, to follow up your welfare, in order to make it possible for the research team to analyze outcomes over a ten year period or longer when possible. | ||
| + | If you rarely post progress or take part in other discussion, you may find it necessary to ask for your personal topic to be reactivated. | ||
| + | You may send an email to our [[mailto: | ||
| //Thank you// | //Thank you// | ||
home/starting.txt · Last modified: 07.04.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.